GAMMA Investing’s Rigel Pharmaceuticals RIGL Stock Holding History

GAMMA Investing’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$36.5K	Sell	932 -5	-0.5%	-$154	﹤0.01%	2511
2026 Q1	$25.3K	Buy	937 +19	+2%	+$638	﹤0.01%	2597
2025 Q4	$39.3K	Buy	918 +37	+4%	+$1.4K	﹤0.01%	2229
2025 Q3	$25K	Buy	881 +3	+0.3%	+$90	﹤0.01%	2414
2025 Q2	$16.4K	Sell	878 -87	-9%	-$1.65K	﹤0.01%	2558
2025 Q1	$17.4K	Buy	965 +881	+1,049%	+$17.9K	﹤0.01%	2473
2024 Q4	$1.41K	Buy	84 +30	+56%	+$575	﹤0.01%	3326
2024 Q3	$874	Buy	+54	New	+$635	﹤0.01%	3291

Other funds holding RIGL

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Burney Company Reston, Virginia $3.71B AUM 37.66% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return

TFA

Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

GAMMA Investing's RIGL Position: Q2 2026 in Review

GAMMA Investing reduced its Rigel Pharmaceuticals (RIGL) stake by 0.53% in Q2 2026, selling an estimated $154 and leaving 932 shares worth $36.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2511.

GAMMA Investing first reported a position in RIGL in Q3 2024 and has held it in 8 quarters since. The position peaked at $39.3K in Q4 2025. 7 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

GAMMA Investing held 932 shares of Rigel Pharmaceuticals worth $36.5K as of Q2 2026.
GAMMA Investing sold 5 Rigel Pharmaceuticals shares in Q2 2026, an estimated $154.
Rigel Pharmaceuticals made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #2511 holding.
GAMMA Investing first reported a position in Rigel Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
GAMMA Investing's Rigel Pharmaceuticals position peaked at $39.3K in Q4 2025.
7 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.